Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab
April 25, 2022 updated by: Bristol-Myers Squibb
This is an expanded access designed to provide access to fixed-dose combination of nivolumab plus relatlimab for eligible participants.
Study Overview
Status
No longer available
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 7, 2022
Primary Completion
December 7, 2022
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
November 17, 2021
First Submitted That Met QC Criteria
December 13, 2021
First Posted (Actual)
December 28, 2021
Study Record Updates
Last Update Posted (Actual)
April 28, 2022
Last Update Submitted That Met QC Criteria
April 25, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA224-129
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nivolumab plus Relatlimab FDC
-
Salzburger LandesklinikenBristol-Myers SquibbRecruitingSquamous Cell Carcinoma of the SkinAustria
-
M.D. Anderson Cancer CenterRecruitingMelanoma (Skin)United States
-
Melanoma Institute AustraliaBristol-Myers SquibbActive, not recruiting
-
Bristol-Myers SquibbTerminatedColorectal NeoplasmsItaly, Canada, Korea, Republic of, Sweden, United States, Argentina, Australia, Austria, Belgium, Chile, China, Czechia, France, Germany, Japan, Netherlands, Poland, Puerto Rico, Singapore, Spain, Switzerland, Taiwan
-
Stanford UniversityRecruitingMelanoma | Brain MetastasesUnited States
-
University of California, San DiegoBristol-Myers SquibbRecruitingBasal Cell CarcinomaUnited States
-
M.D. Anderson Cancer CenterBristol-Myers SquibbRecruitingRenal Cell Carcinoma, Clear CellUnited States
-
ModernaTX, Inc.Not yet recruitingAdvanced Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced MelanomaUnited States
-
Bristol-Myers SquibbNot yet recruitingMetastatic Melanoma | Unresectable Melanoma | Untreated MelanomaIndia